Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Licenses Nanogen's MGB Probes for Use with Upcoming miRNA Diagnostics

NEW YORK (GenomeWeb News) - Rosetta Genomics said today that it has licensed Nanogen’s MGB Probe technology for use with a line of microRNA biomarker-based diagnostic tests that it plans to launch in 2008.
 
Rosetta plans to use the MGB, or minor groove binder, probes to develop a line of real-time PCR-based diagnostic tests.
 
Rosetta said it expects to launch three tests in 2008: one that will differentiate squamous from non squamous lung cancers; another to differentiate mesothelioma from lung adenocarcinoma; and another to identify the origin of tumors in cancer cases where this is not known. The company said clinicians cannot identify the origin of metastases in between three and five percent of all cancer patients.
 
Financial terms of the licensing agreement with Nanogen were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.